Retension Pharmaceuticals: director Donald Olds received 5,637 shares

What happened

• Donald Olds, a director, had 5,637 shares of common stock acquired on Oct 13, 2026 through conversion of a derivative security and the filing also shows a disposition of 5,637 shares of the derivative security. The filing lists prices and total value as N/A.

Key details

• Transaction date: Oct 13, 2026; price: N/A.
• Shares acquired: 5,637 common shares; derivative shares disposed: 5,637.
• Shares owned after the transaction: not reported in this filing.
• Footnote: the Series A convertible preferred stock converted automatically into one share of common stock immediately prior to the issuer's initial public offering without payment of consideration; the Series A preferred had no expiration date.
• Filing date: Oct 13, 2026.

Why it may matter

• This was a conversion of a derivative security into common stock, not a market purchase or sale.
• The filing does not show why the insider traded or why the company acted.